GT Biopharma
GTBP

GT Biopharma (GTBP) earnings history

Most recent quarter

Period end
Jun 30, 2025
EPS actual
−$13.75
EPS estimate
−$17.00
Revenue
$0.00
Reported
Aug 14, 2025

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2025Aug 14, 2025−$17.00−$13.75+19.12%$0.00SEC
Q1 2025May 15, 2025−$8.25−$8.25+0.00%$0.00SEC
Q4 2024Feb 21, 2025−$38.75−$41.75−7.74%$0.00SEC
Q3 2024Nov 14, 2024−$67.50−$38.25+43.33%$0.00SEC
Q2 2024Aug 14, 2024−$67.50−$54.25+19.63%$0.00SEC
Q1 2024May 15, 2024−$67.50−$41.00+39.26%$0.00SEC
Q3 2023Nov 1, 2023−$63.75−$45.00+29.41%$0.00SEC
Q2 2023Aug 7, 2023−$75.00−$41.26+44.98%$0.00SEC
Q1 2023May 15, 2023−$108.75−$7.50+93.10%$0.00SEC
Q4 2022Mar 30, 2023−$131.25−$135.00−2.86%$0.00SEC
Q3 2022Oct 31, 2022−$82.50−$165.00−100.00%$0.00—
Q2 2022Aug 15, 2022−$131.25−$75.00+42.86%$0.00—
Q1 2022May 16, 2022−$232.50−$127.50+45.16%$0.00—
Q4 2021Mar 28, 2022−$147.50−$423.75−187.29%$0.00—
Q3 2021Nov 10, 2021−$117.50−$146.86−24.99%$0.00—
Q2 2021Aug 23, 2021−$207.50−$112.50+45.78%$0.00—
Q1 2021May 17, 2021−$183.75−$1,372.50−646.94%$0.00—
Q4 2020Apr 16, 2021−$86.25−$1,241.25−1339.13%$0.00—

Quarterly revenue

Q4 2020
$0.00
Q1 2021
$0.00
Q2 2021
$0.00
Q3 2021
$0.00
Q4 2021
$0.00
Q1 2022
$0.00
Q2 2022
$0.00
Q3 2022
$0.00
Q4 2022
$0.00
Q1 2023
$0.00
Q2 2023
$0.00
Q3 2023
$0.00
Q1 2024
$0.00
Q2 2024
$0.00
Q3 2024
$0.00
Q4 2024
$0.00
Q1 2025
$0.00
Q2 2025
$0.00

Frequently asked questions

  • When did GT Biopharma (GTBP) last report earnings?

    GT Biopharma last reported on Aug 14, 2025, covering fiscal Q2 2025.

  • Did GTBP beat earnings estimates?

    Yes. GT Biopharma reported EPS of −$13.75 for Q2 2025 against a −$17.00 estimate — a 19.12% beat.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.